Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 8/20 | 0.55 |
| ▸ | CASP7 | P55210 | 6/20 | 0.51 |
| ▸ | CASP1 | P29466 | 5/20 | 0.51 |
| ▸ | CASP9 | P55211 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | CASP4 | P49662 | 2/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3140616 | 0.89 | CASP3 (0.62) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL614741 | 0.89 | CASP3 (0.62) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL28840715 | 0.88 | CASP3 (0.55) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL811863 | 0.88 | CASP3 (0.55) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL17803368 | 0.88 | CASP3 (0.55) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL18740358 | 0.88 | CASP3 (0.58) | CASP3CASP7CASP1CASP9CTSB | |
| SCHEMBL24213871 | 0.87 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP8 | |
| SCHEMBL17494194 | 0.87 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP8 | |
| SCHEMBL7112627 | 0.87 | CASP3 (0.58) | CASP3CASP7CASP1CASP9ELANE | |
| SCHEMBL14646635 | 0.87 | CASP3 (0.56) | CASP3CASP7CASP1CASP9CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163459-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2025-05-22 | — | — | US | claimed |
| EP-4486872-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2025-01-08 | — | — | EP | claimed |
| CN-118804973-A | Improved cell lines and methods for producing adeno-associated vectors | 塞维克制药有限责任公司 | 2024-10-18 | — | — | CN | claimed |
| WO-2023166026-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2023-09-07 | — | — | WO | claimed |
| EP-4239063-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2023-09-06 | — | — | EP | claimed |
| US-20250332213-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | PRONEUROGEN INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250281566-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | PRONEUROGEN INC (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2025122650-A1 | EXTRACELLULAR VESICLE-BASED BIOMARKER DETECTION | Sunbird Bio, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250163459-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2025-05-22 | — | — | US | disclosed |
| US-20250012814-A1 | METHODS OF DIAGNOSING A SYNUCLEINOPATHY | NITRASE THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4486872-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2025-01-08 | — | — | EP | disclosed |
| CN-118804973-A | Improved cell lines and methods for producing adeno-associated vectors | 塞维克制药有限责任公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4319721-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | Proneurogen, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023166026-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC PHARMACEUTICALS GMBH (DE) | 2023-09-07 | — | — | WO | disclosed |
| EP-4239063-A1 | IMPROVED CELL LINES AND METHODS FOR THE PRODUCTION OF ADENO-ASSOCIATED VECTORS | CEVEC Pharmaceuticals GmbH (DE) | 2023-09-06 | — | — | EP | disclosed |
| WO-2023077122-A1 | METHODS OF DIAGNOSING A SYNUCLEINOPATHY | NITRASE THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-3558335-B1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP AID INC (CA) | 2023-04-19 | — | — | EP | disclosed |
| US-20220331395-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | PRONEUROGEN, INC. | 2022-10-20 | — | — | US | disclosed |
| WO-2022216941-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | PRONEUROGEN, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220054454-A1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP-AID INC. (CA) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054454-A1 | CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS | CASP1, CASP5, CASP10 | CASP3 10/4885CASP7 12/4885CASP1 1/4885 |
| US-20250332213-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | AGT, ACE, DNPEP | CASP3 2672/4885CASP7 768/4885CASP1 3229/4885 |
| US-20250281566-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | AGT, ACE, DNPEP | CASP3 2672/4885CASP7 768/4885CASP1 3229/4885 |
| US-20220331395-A1 | EXTENDED-RELEASE INJECTABLE GEL FORMULATIONS CONTAINING ANGIOTENSIN-(1-7) OLIGOPEPTIDES OR VARIANTS THEREOF | AGT, ACE, DNPEP | CASP3 2672/4885CASP7 768/4885CASP1 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.